Long-term follow up Helicobacter Pylori reinfection rate after second-line treatment: bismuth-containing quadruple therapy versus moxifloxacin-based triple therapy

BMC Gastroenterology

Research Article

Cheol Min Shin¹  Min Soo Kim¹  Sung Eun Kim¹  Hyun Jin Jo¹  Dong Ho Lee²  Nayoung Kim²  Young Soo Park² 

[1] Department of Internal Medicine, Seoul National University Bundang Hospital, Seongnam, Gyeonggi-do, South Korea;Department of Internal Medicine, Seoul National University Bundang Hospital, Seongnam, Gyeonggi-do, South Korea;Department of Internal Medicine and Liver Research Institute, Seoul National University College of Medicine, Seoul, South Korea;

关键词: Helicobacter pylori;    Reinfection;    Quadruple;    Moxifloxacin;    Second-line;   

DOI  :  10.1186/1471-230X-13-138

 received in 2013-02-01, accepted in 2013-09-12,  发布年份 2013

来源: Springer

【 摘 要 】

BackgroundThe increasing trend of antibiotic resistance requires effective second-line Helicobacter pylori (H. pylori) treatment in high prevalence area of H. pylori. The aim of our study was to evaluate the reinfection rate of H. pylori after second-line treatment that would determine the long-term follow up effect of the rescue therapy.MethodsA total of 648 patients who had failed previous H. pylori eradication on standard triple therapy were randomized into two regimens: 1, esomeprazole (20 mg b.i.d), tripotassium dicitrate bismuthate (300 mg q.i.d), metronidazole (500 mg t.i.d), and tetracycline (500 mg q.i.d) (EBMT) or 2, moxifloxacin (400 mg q.d.), esomeprazole (20 mg b.i.d), and amoxicillin (1000 mg b.i.d.) (MEA). At four weeks after completion of eradication therapy, H. pylori tests were performed with 13C urea breath test or invasive tests. In patients who maintained continuous H. pylori negativity for the first year after eradication therapy, H. pylori status was assessed every year. For the evaluation of risk factors of reinfection, gender, age, clinical diagnosis, histological atrophic gastritis or intestinal metaplasia were analyzed.ResultsThe recrudescence rate of the EBMT was 1.7% and of the MEA group 3.3% (p = 0.67). The annual reinfection rate of H. pylori of EBMT was found to be 4.45% and the MEA group 6.46%. Univariate analysis (Log-rank test) showed no association with any clinical risk factor for reinfection.ConclusionsThe long-term reinfection rate of H. pylori stayed low in both of bismuth-containing quadruple therapy and moxifloxacin-based triple therapy; thus reinfection cannot affect the choice of second-line treatment.Trial registrationClinical Trial Registration Number NCT01792700

【 授权许可】

CC BY   
© Kim et al.; licensee BioMed Central Ltd. 2013